BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations
Sarah A Holstein1, Hervé Avet-Loiseau2, Theresa Hahn3
1Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
Insights
Minimal residual disease assessment and immune profiling are crucial for myeloma research. This workshop focused on integrating these advanced techniques into future clinical trials for better outcomes.
Area of Science:
- Hematology
- Clinical Trials
- Immunology
Background:
- The Blood and Marrow Transplant Clinical Trials Network convened a workshop to address minimal residual disease (MRD) and immune profiling in myeloma.
- Emerging data and technologies in MRD assessment and immune profiling necessitate strategic integration into clinical research.
Purpose of the Study:
- To discuss current advancements in MRD and immune profiling for multiple myeloma.
- To develop strategies for incorporating these techniques into clinical trial design.
- To provide recommendations for future myeloma clinical trials.
Main Methods:
- Literature review on MRD and immune profiling in myeloma.
- Summary of discussions from the Myeloma Intergroup Workshop.
- Formulation of recommendations for clinical trial integration.
Main Results:
- Key data and technologies for MRD and immune profiling were reviewed.
- Strategies for integrating these assessments into clinical trials were discussed.
- Recommendations were developed for future clinical trial design.
Conclusions:
- Integrating MRD and immune profiling into myeloma clinical trials is essential.
- Standardized approaches are needed for consistent data collection and analysis.
- These advancements hold promise for improving patient stratification and treatment efficacy in myeloma.
Abstract:
The Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 1, 2016 at the American Society of Hematology meeting to discuss the emerging data and technologies for minimal residual disease assessment and immune profiling in myeloma. Particular emphasis was placed on developing strategies to incorporate these techniques into clinical trial design. This document reviews the literature, summarizes the topics discussed in the workshop, and provides recommendations for integration of these techniques into future clinical trial design.
